by Jang Hyowon
Published 18 Oct.2024 13:51(KST)
CreoSG announced on the 18th that it will participate in the regular academic conference hosted by the International Society for Vaccines (ISV) from the 21st to the 23rd and present its achievements in the development of the MERS vaccine pipeline. Through this event, CreoSG plans to secure joint research and development, commercialization partners, and attract investment.
The ISV regular academic conference is an international event attended by experts in the field of vaccine research worldwide. It is held annually on various topics including human and animal preventive vaccines, therapeutic vaccines, and immunotherapy. Not only researchers but also governments and investors from around the world participate to engage in business discussions.
CreoSG is scheduled to present its own vaccine development status and technological capabilities in the MERS vaccine session. The company explained that through this event, it will share the research and development achievements of its proprietary technology-based MERS vaccine and seek joint research and investment institutions.
CreoSG is developing a MERS vaccine based on its proprietary recombinant vesicular stomatitis virus (rVSV) technology. Applying rVSV technology is characterized by securing vaccine safety and maximizing immune response. During animal experiments, CreoSG confirmed that administration of its vaccine induced an immune response against the MERS virus and completely suppressed viral infection.
A CreoSG official said, “We have maintained a continuous cooperative relationship with the International Vaccine Institute (IVI) and will present at the session hosted by IVI. Through the academic conference, we plan to introduce CreoSG’s technological competitiveness and actively explore various cooperation plans to accelerate MERS vaccine development.”
He added, “When the vaccine applying CreoSG’s rVSV technology is administered, a significant protein-binding antibody and neutralizing antibody response is induced, T-cell immunogenicity was excellent, and immune responses were sustained even after a certain period. Based on this differentiated competitiveness, we plan to pursue partnering and technology transfer with countries in the Middle East region where MERS incidence is high.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.